China National Medical Products Administration approves Tislelizumab in combination with chemotherapy in first-line advanced squamous Non-Small Cell Lung Cancer (NSCLC)

 PRESS RELEASE   01/2021

BEIJING & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jan. 13, 2021-- BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that its anti-PD-1 antibody tislelizumab has received approval from the China National Medical Products Administration (NMPA) for use in combination with two chemotherapy regimens as a first-line treatment for patients with advanced squamous non-small cell lung cancer (NSCLC). This is the third approval in China for tislelizumab, and its first in a lung cancer indication.


Rate this resource